Correlation Between Purple Biotech and Monopar Therapeutics

Can any of the company-specific risk be diversified away by investing in both Purple Biotech and Monopar Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Purple Biotech and Monopar Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Purple Biotech and Monopar Therapeutics, you can compare the effects of market volatilities on Purple Biotech and Monopar Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Purple Biotech with a short position of Monopar Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Purple Biotech and Monopar Therapeutics.

Diversification Opportunities for Purple Biotech and Monopar Therapeutics

-0.49

Correlation Coefficient

Purple Biotech  Monopar Therapeutics

Very good diversification

The 3 months correlation between Purple and Monopar is -0.49. Overlapping area represents the amount of risk that can be diversified away by holding Purple Biotech and Monopar Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Monopar Therapeutics and Purple Biotech is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Purple Biotech are associated (or correlated) with Monopar Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Monopar Therapeutics has no effect on the direction of Purple Biotech i.e., Purple Biotech and Monopar Therapeutics go up and down completely randomly.

Pair Corralation between Purple Biotech and Monopar Therapeutics

Given the investment horizon of 90 days Purple Biotech is expected to under-perform the Monopar Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Purple Biotech is 2.2 times less risky than Monopar Therapeutics. The stock trades about -0.18 of its potential returns per unit of risk. The Monopar Therapeutics is currently generating about 0.15 of returns per unit of risk over similar time horizon. If you would invest  2,385  in Monopar Therapeutics on December 28, 2024 and sell it today you would earn a total of  1,754  from holding Monopar Therapeutics or generate 73.54% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Purple Biotech  vs.  Monopar Therapeutics

Purple Biotech

Risk-Adjusted Performance

Very Weak

Over the last 90 days Purple Biotech has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's fundamental drivers remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Monopar Therapeutics

Risk-Adjusted Performance

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Monopar Therapeutics are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak basic indicators, Monopar Therapeutics reported solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Purple Biotech and Monopar Therapeutics

The main advantage of trading using opposite Purple Biotech and Monopar Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Purple Biotech position performs unexpectedly, Monopar Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Monopar Therapeutics will offset losses from the drop in Monopar Therapeutics' long position.

The idea behind Purple Biotech and Monopar Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.